Ameritox is the nation’s leader in pain medication monitoring, offering laboratory services and practice management tools to help clinicians coordinate and optimize the care of chronic pain patients. Ameritox’s pain medication monitoring includes the patented Rx GuardianSM process, which goes beyond standard urine drug testing to help clinicians assess whether patients are taking their medications correctly.
In 2011 Ameritox introduced Rx Guardian CDSM, featuring a proprietary normalization algorithm and the most comprehensive reference database of pain patients who were clinically assessed for adherence. Rx Guardian CDSM compares patients’ results to the reference database, providing clinicians with added assurance in assessing patients’ pain medication adherence. This helps clinicians identify potential abuse, misuse, or diversion of patient medication.
Ameritox Ltd. was originally founded in 1996 as Universal Toxicology Laboratories (UTL), a federally certified urine drug testing facility and medical examiner toxicology laboratory. Ameritox is now headquartered in Baltimore, Md., with laboratories in Midland, Texas, and Greensboro, N.C..
Our research program collaborates with top academic, research, and pain centers, including Beth Israel Medical Center and Thomas Jefferson School of Population Health, and leads the industry with an innovative research program that’s redefining the field of pain medication monitoring, including:
- Five published studies and ten accepted poster presentations at major pain conferences in the last two years.
- A study of nearly one million urine drug tests showed that likely nonadherence and drug misuse are very common across all age and demographic groups of patients on chronic opioid therapy.
- A health economics study analyzed managed care claims of more than 18 million patients, finding that patients undergoing opioid therapy for chronic pain who may not be following their prescription regimen have significantly higher overall healthcare costs.
- The establishment of a Scientific Advisory Board, comprised of leading experts in pain medicine, providing guidance on clinical research, pain management, and establishing the role of urine drug monitoring in pain monitoring.
These research and clinical advances have greatly enhanced and expanded the tools that Ameritox offers to physicians. Our expertise and innovative science provide insights and support that enable physicians to enhance and optimize the care they provide for their chronic pain patients.
The Ameritox management team includes some of the industry’s most respected scientists, clinicians, researchers and business leaders. Under this leadership, Ameritox is advancing the pain medication monitoring industry and continues to invest in new approaches to pain medication monitoring solutions.
Contact Ameritox today to find out how pain medication monitoring can help you better manage outcomes for your pain patients.